Browse our 650+ Publications
Latest Publications
Long-term follow-up of patients with follicular lymphoma using next generation sequencing to detect minimal residual disease
Clinical Lymphoma Myeloma & Leukemia
April 2024
Authors and Affiliates
Ayushi Chauhan2, Catherine Lai4 Frank Kuhr3, Heidi Simmons3, Bruce D. Cheson1
1- Center for Cancer and Blood Disorders, Bethesda, MD; 2- Medical College of Georgia,
Augusta, Georgia; 3-Adaptive Biotechnologies, Seattle, WA; 4-University of Pennsylvania,
Perelman Center for Advanced Medicine, Philadelphia, PA
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results
Leukemia
March 2024
Authors and Affiliates
Liora M. Schultz1,2,6, Nikeshan Jeyakumar3,6, Anne Marijn Kramer 2, Bita Sahaf2, Hrishi Srinagesh3, Parveen Shiraz4, Neha Agarwal4,
Mark Hamilton3, Courtney Erickson1, Ashley Jacobs1, Jennifer Moon1, Christina Baggott1, Sally Arai4, Sushma Bharadwaj4,
Laura J. Johnston4, Michaela Liedtke3, Robert Lowsky4, Everett Meyer4, Robert Negrin4, Andrew Rezvani4, Judy Shizuru 4,
Surbhi Sidana 4, Emily Egeler2, Sharon Mavroukakis2, Ramya Tunuguntla5, Nikolaos Gkitsas-Long5, Aidan Retherford5,
Annie Kathleen Brown5, Anne-Louise Gramstrap-Petersen5, Raquel Martin Ibañez5, Steven A. Feldman2,5, David B. Miklos 2,4,
Crystal L. Mackall 1,2, Kara L. Davis1,2, Matthew Frank2,4, Sneha Ramakrishna1,2 and Lori Muffly 2,4
1Division of Pediatric Hematology/Oncology, Stanford University, Stanford, CA, USA. 2Center for Cancer Cell Therapy, Stanford University, Stanford, CA, USA. 3Division of
Hematology, Stanford University, Stanford, CA, USA. 4Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA. 5Laboratory for
Cell and Gene Medicine, Stanford University, Stanford, CA, USA. 6These authors contributed equally: Liora M. Schultz, Nikeshan Jeyakumar. ✉email: lmuffly@stanford.edu
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia
Jabbour E, et al.
American Journal of Hematology
February 2024
Authors and Affiliates
Elias Jabbour1 | Gerhard Zugmaier2 | Vaibhav Agrawal3 |
Pilar Martínez-Sánchez4 | José J. Rifon Roca5 | Ryan D. Cassaday6,7 |
Boris Böll8 | Anita Rijneveld9 | Maher Abdul-Hay10 | Françoise Huguet11 |
Thomas Cluzeau12 | Mar Tormo Díaz13 | Vladan Vucinic14 |
José González-Campos15 | Alessandro Rambaldi16 | Stefan Schwartz17 |
Céline Berthon18 | Jesús María Hernández-Rivas19,20,21 | Paul R. Gordon22 |
Monika Brüggemann23 | Ali Hamidi22 | Yuqi Chen22 | Hansen L. Wong24 |
Bharat Panwar22 | Yuliya Katlinskaya22 | Ana Markovic22 | Hagop Kantarjian1
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
2Amgen Research (Munich), GmbH, Munich, Germany
3Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte,
California, USA
4Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain
5Hematology and Hemotherapy Department, Clínica Universidad de Navarra, Pamplona, Spain
6Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA
7Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA
8First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany
9Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands
10Perlmutter Cancer Center, New York University Langone Health, New York, New York, USA
11Department of Hematology, Institut Universitaire du Cancer-Oncopole CHU de Toulouse, Toulouse, France
12Université Nice Côte d'Azur, CHU de Nice, Nice, France
13Hematology Department, Hospital Clínico Universitario de Valencia, Instituto de Investigacion Sanitaria INCLIVA, Valencia, Spain
14Department of Hematology and Cell Therapy, University Hospital Leipzig, Leipzig, Germany
15Hematology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
16Department of Oncology-Hematology, University of Milan, Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
17Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-
Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany
18Centre Hospitalier Universitaire de Lille, Lille, France
19IBSAL, IBMCC, CSIC, Cancer Research Center, University of Salamanca, Salamanca, Spain
20Department of Hematology, University Hospital of Salamanca, Salamanca, Spain
21CIBERONC, Research Group CB16/12/00233, Salamanca, Spain
22Amgen Inc., Thousand Oaks, California, USA
23Department of Hematology, University of Schleswig-Holstein, Kiel, Germany
24Clinical Pharmacology, Modeling and Simulation, Amgen Inc., South San Francisco, California, USA
Isatuximab in combination with carfilzomib anddexamethasone in 1q21þ patients with relapsed/refractorymultiple myeloma: Long‐term outcomes in the Phase 3 IKEMA study
Facon T, et al.
hematological oncology
February 2024
Authors and Affiliates
Thierry Facon1 | Philippe Moreau2 | Ivan Špicka3 | Kenshi Suzuki4 |
Kwee Yong5 | Joseph Mikhael6 | Taro Fukao7 | Kamlesh Bisht7 |
Nicole M. Armstrong8 | Sandrine Macé9 | Marie‐Laure Risse10 | Thomas Martin11
1Department of Hematology, Lille University
Hospital, Lille, France
2Department of Hematology, University
Hospital Hôtel‐Dieu, Nantes, France
3Department of Hematology, 1st Faculty of
Medicine, Charles University and General
Hospital, Prague, Czech Republic
4Myeloma/Amyloidosis Center, Japanese Red
Cross Medical Center, Tokyo, Japan
5Department of Haematology, University
College Hospital, London, UK
6Translational Genomics Research Institute,
City of Hope Cancer Center, Phoenix,
Arizona, USA
7Sanofi, Global Oncology, Cambridge,
Massachusetts, USA
8Sanofi, Global Medical Affairs, Cambridge,
Massachusetts, USA
9Sanofi, Research and Development, Chilly‐
Mazarin, France
10Sanofi, Research and Development, Vitry‐
Sur‐Seine, France
11University of California San Francisco
Medical Center, San Francisco, California, USA
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia
Stilgenbauer S, et al.
Blood Advances
January 2024
Authors and Affiliates
Stephan Stilgenbauer,1 Eugen Tausch,1 Andrew W. Roberts,2 Matthew S. Davids,3 Barbara Eichhorst,4
Michael Hallek,4 Peter Hillmen,5 Christof Schneider,1 Johannes Schetelig,6 Sebastian Böttcher,7 Arnon P.
Kater,8 Yanwen Jiang,9 Michelle Boyer,9 Relja Popovic,10 Majd T. Ghanim,10 Michael Moran,10 Wendy J.
Sinai,10 Xifeng Wang,10 Nabanita Mukherjee,10 Brenda Chyla,10 William G. Wierda,11,* John F. Seymour2,*
1Division of CLL, Internal Medicine III, Ulm University, Ulm, Germany; 2Peter MacCallum Cancer Centre,
Royal Melbourne Hospital, and University of Melbourne, Melbourne, Australia; 3Department of Medical
Oncology, Dana-Farber Cancer Institute, Boston, MA; 4Department of Internal Medicine, Center of
Integrated Oncology Köln Bonn, University Hospital of Cologne, Cologne, Germany; 5Leeds Teaching
Hospitals, NHS Trust, Leeds, United Kingdom; 6University Hospital, Technische Universität Dresden,
Dresden, Germany; 7Division of Internal Medicine, Medical Clinic III-Hematology, Oncology and Palliative
Medicine, Rostock University Medical Center, Rostock, Germany; 8Department of Hematology, Cancer
Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands; 9Genentech,
South San Francisco, CA; 10AbbVie Inc, North Chicago, IL; 11The University of Texas MD Anderson Cancer
Center, Houston, TX
*Contributed equally.
Daratumumab in Myeloma Patients With Early or Late Relapse After Initial Therapy: Subgroup Analysis of CASTOR and POLLUX.
Spencer A, et al.
Blood Advances
January 2024
Authors and Affiliates
Andrew Spencer, Philippe Moreau, M V Mateos, Hartmut Goldschmidt, Kenshi Suzuki, Mark-David Levin, Pieter Sonneveld, Robert Z Orlowski, Sung-Soo Yoon, Saad Z Usmani, Katja C Weisel, Donna Reece, Tahamtan Ahmadi, Huiling Pei, Wendy Garvin Mayo, Xue Gai, Jodi Carey, J Blake Bartlett, Robin Carson, Meletios-Athanasios A Dimopoulos
Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma.
Rezazadeh A, et al.
Clinical Lymphoma Myeloma & Leukemia
January 2024
Authors and Affiliates
Alexandra Rezazadeh, Julie Pruett, Amy Detzner, Natasha Edwin, Mehdi Hamadani, Nirav N Shah, Timothy S Fenske
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma.
Karmali R, et al.
Blood Advances
December 2023
Authors and Affiliates
Reem Karmali, Jeremy S Abramson, Deborah M Stephens, Jeffrey Barnes, Jane N Winter, Shuo Ma, Juehua Gao, Jason Kaplan, Adam M Petrich, Ephraim Hochberg, Tak Takvorian, Xinlei Mi, Valerie Nelson, Leo I Gordon, Barbara Pro
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, et al.
New England Journal of Medicine
December 2023
Authors and Affiliates
Pieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, Hang Quach, P Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S Nijhof, Niels W C J van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda Balari, Laura Rosiñol, Michel Delforge, Wilfried Roeloffzen, Tobias Silzle, Annette Vangsted, Hermann Einsele, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M J van Brummelen, Veronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J de Boer, Robin Carson, Paula Rodriguez-Otero, Joan Bladé, Philippe Moreau; PERSEUS Trial Investigators
Previous
Next